Pandemic Response Solutions™
An influenza pandemic occurs when a new flu virus emerges for which humans have little or no immunity, allowing the virus to spread rapidly from person to person worldwide.
Experts agree there will be another influenza pandemic this century. Although it cannot be determined when or what influenza strain will start to spread among humans, the world must be prepared for such an event. When millions of lives are at stake, a daunting challenge remains to provide rapid access to adequate pandemic vaccines and medical countermeasures.
CSL Seqirus is a global leader in influenza vaccines with proven experience in providing governments with reliability and confidence in innovative solutions for pandemic preparedness and response.
Enhancing Pandemic Response
With our heritage and unique capabilities, along with our global manufacturing network, we have systemized the process of preparing for influenza pandemic outbreaks and work with numerous governments to support their influenza vaccine pandemic preparedness needs. Our dual production platforms and MF59® antigen-sparing technology4 underpin our commitment to rapidly supply pandemic influenza vaccines when needed.
A Comprehensive Portfolio of Solutions
We offer a portfolio of pre-pandemic and pandemic influenza vaccines through agreements signed with governments as well as with the World Health Organization. These agreements ensure that pandemic influenza dose capacity is reserved and can be deployed upon the declaration of a pandemic. Some governments have policies to protect First-Responders with early access to pandemic vaccine doses. Many of these governments rely on CSL Seqirus to provide pre-pandemic stockpiles of antigen and MF59® adjuvant that could be quickly combined in the early phase of a global outbreak.
In the event of an influenza pandemic, CSL Seqirus commits to a rapid and reliable response through the provision of reserved pandemic vaccine doses. Our pre-pandemic and pandemic influenza vaccines are licensed in a number of countries. We continue to test pre-pandemic candidate vaccines produced on our manufacturing platforms. Our ongoing projects are aimed at accelerating our response, via further surge capacity enhancement.
CSL Seqirus works with governments around the world to support influenza pandemic readiness and emergency response.
1. Infectious Disease Society of America. Public Health, Influenza, What is Pandemic Influenza? Infectious Disease Society of America website. https://www.idsociety.org/public-health/influenza/influenza-main-page/what-is-pandemic-influenza (Accessed October 2020).
2. The World Bank, International Working Group on Financing Preparedness. From Panic and Neglect to Investing in Health Security: Financing Pandemic Preparedness at a National Level. December 2017. Retrieved from: http://documents.worldbank.org/curated/en/979591495652724770/From-panic-and-neglect-to-investing-in-health-security-financing-pandemic-preparedness-at-a-national-level (Accessed October 2020).
3. Berthe, Frank Cesar Jean et al, The World Bank. One Health: Operational Framework for Strengthening Human, Animal, and Environmental Public Health Systems at their Interface. January 2018qirus UK Limited.. Retrievedtober 2020 from: http://documents.worldbank.org/curated/en/961101524657708673/One-health-operational-framework-for-strengthening-human-animal-and-environmental-public-health-systems-at-their-interface (Accessed October 2020).
4. O'Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD. The history of MF59® adjuvant: a phoenix that arose from the ashes. Expert Review of Vaccines 2013; 12:13-30. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/23256736 (Accessed October 2020).
MF59® is a trademark of Seqirus UK Limited.